Brolucizumab: First Approval
- 158 Downloads
Brolucizumab (Beovu®) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being developed by Novartis for the treatment of exudative (wet) age-related macular degeneration (AMD), diabetic macular oedema and macular oedema secondary to retinal vein occlusion. Based primarily on the results of the phase III HAWK and HARRIER trials brolucizumab was recently approved in the US for the treatment of wet AMD. This article summarizes the milestones in the development of brolucizumab leading to this first approval.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
- 2.Novartis. Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept [media release]. 8 Oct 2019. https://www.prnewswire.com.
- 3.Alcon. Alcon to acquire Swiss biotechnology firm, ESBATech AG [media release]. 14 Sep 2009. http://www.alcon.com.
- 4.Alcon. Alcon and Novartis complete merger and form new Alcon Division to accelerate global leadership in eye care [media release]. 8 Apr 2011. http://www.alcon.com.
- 5.Novartis. Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off [media release]. 9 Apr 2019. http://www.novartis.com.
- 6.Gaudreault J, Gunde T, Floyd HS, et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53(14):3025.Google Scholar
- 7.Tietz J, Spohn G, Schmid G, et al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor a for the treatment of retinal disorders [abstract]. Invest Ophthalmol Vis Sci. 2015;56(7):1501.Google Scholar
- 9.Nimz EL, Van TLCW, Yanez JA, et al. Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates [abstract]. Invest Ophthalmol Vis Sci. 2016;57(12):4996.Google Scholar
- 11.Singh RP, Wykoff CC, Tadayoni R, et al. Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER [abstract]. Investig Ophthalm Vis Sci. 2019;60(9):5194.Google Scholar
- 12.Dugel PU, Lang GE, Razavi S, et al. Predictability of the 12-week dosing status at week 48 for patients receiving brolucizumab in HAWK and HARRIER [abstract]. Investig Ophthalm Vis Sci Conf. 2018;59(9):1455.Google Scholar